Samsung Biologics Completes Purchase Of Samsung Bioepis | Contract Pharma
Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets | Be Korea-savvy
Samsung Biologics and Biogen Idec to form Samsung Bioepis
Samsung Bioepis enters US market for biosimilars of Humira - KED Global
o9 to supply AI-powered IBP platform to Samsung Bioepis
Samsung Bioepis' Biologics License Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the U.S. Food and Drug Administration | Business Wire
FDA Accepts Ranibizumab BLA From Samsung Bioepis and Biogen
Samsung Bioepis Obtains Two ISO Certifications for Environmental Management System and Energy Management System - ESG News
Samsung Bioepis gets nod for sale of biosimilar drug in Europe | Yonhap News Agency
Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada - KED Global
Innovations in Biosimilars: Insights and Trends from Samsung Bioepis - Xtalks
Samsung Bioepis DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP
Amgen withdraws patent suit against Samsung Bioepis
Merck to develop biosimilars with Samsung-Biogen joint venture - PMLiVE
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging
PharmaBoardroom - Samsung Bioepis
Samsung Biologics completes full acquisition of Samsung Bioepis | World Pharma Today
SAMSUNG BIOEPIS
Samsung's three biosimilars generate sales of nearly $800 mn in Europe last year - Pulse by Maeil Business News Korea
Samsung on Samsung: Bioepis selects Biologics as a biosimilars CMO
Samsung Biologics - Wikipedia
Samsung Biologics completes full acquisition of Samsung Bioepis
